Top-line results from the Phase IIIa FRONTIER 2 trial show a positive treatment effect for Novo Nordisk’s (NOV: N) hemophilia A treatment Mim8.
The once-weekly and once-monthly subcutaneous injection was compared with those who had no prior prophylaxis and with those who had prior coagulation factor prophylaxis treatment.
The trial achieved its co-primary endpoints by demonstrating a statistically-significant and superior reduction of treated bleeding episodes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze